Information  X 
Enter a valid email address

Oxford Glycosciences (OGS)

  Print   

Wednesday 09 April, 2003

Oxford Glycosciences

Notice of Results

Oxford Glycosciences PLC
09 April 2003

Oxford GlycoSciences Plc

09 April 2003



Not for release, publication or distribution in, into or from Australia, Canada
or Japan



                        OXFORD GLYCOSCIENCES PLC ('OGS')

                         RELEASE OF PRELIMINARY RESULTS



OGS intends to release preliminary results for the year ended 31 December 2002
on or about 29 April 2003.



OGS directs shareholders to the announcement by the Panel on Takeovers and
Mergers on the impact of the timing of this release on the offer timetables for
both the offers by Cambridge Antibody Technology Group plc and Celltech Group
plc.



                                     -Ends-



For further information please contact:



Oxford GlycoSciences Plc
David Ebsworth, Ph.D., Chief Executive Officer          +44 (0) 1235 208 000



Goldman Sachs International
Michael Hill                                            +44 (0) 20 7774 1000
Basil Geoghegan
Phil Raper (Corporate Broking)




Financial Dynamics
UK Media and Investors                                  +44 (0) 20 7831 3113
Tim Spratt
Melanie Toyne-Sewell

US Media and Investors                                  +1 212 850 5626
Leslie Wolf-Creutzfeldt
Deborah Ardern Jones



Goldman Sachs International is acting for OGS and for no-one else in connection
with this announcement and will not be responsible to any other person for
providing the protections afforded to clients of Goldman Sachs International or
for providing advice in relation to the offer from Celltech, the merger with
Cambridge Antibody Technology Group plc ('CAT') or the contents of this
announcement.



The directors of OGS accept responsibility for the information contained in this
announcement.  To the best of the knowledge and belief of the directors of OGS
(who have taken all reasonable care to ensure that such is the case), the
information contained in this announcement is in accordance with the facts and
does not omit anything likely to affect the import of such information.*



*Dr Donald Drakeman, a director of OGS, is also the Chief Executive Officer of
Medarex Inc, a competitor of CAT, and therefore did not participate in decisions
of the OGS Board relating to the merger with CAT.  Given this conflict, he has
also not participated and does not propose to participate in discussions
relating to any competing offer for OGS.  Accordingly, Dr Drakeman has abstained
from OGS Board discussions of, and advice to OGS shareholders relating to, the
merger with CAT and the offer from Celltech and is not taking responsibility for
the views or advice of the Board on the merger with CAT or the offer from
Celltech.



Shareholders can obtain a free copy of this and any other documents filed with
the Securities and Exchange Commission at the SEC's website (www.sec.gov).



This announcement does not constitute an offer to sell or invitation to purchase
any securities or the solicitation of any vote or approval in any jurisdiction.



The release, publication or distribution of this announcement in certain
jurisdictions may be restricted by law and therefore persons in such
jurisdictions into which this announcement is released, published or distributed
should inform themselves about and observe such restrictions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange                                                                                                                                                                     

a d v e r t i s e m e n t